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Introduction
The human creatine transporter 1 (hCRT-1, SLC6A8) belongs to the sodium dependent neurotransmitter family of solute carrier 6 (SLC6) transporters. It is a protein of 635 amino acid residues, organised into twelve transmembrane spanning helices (TM1-TM12). Over the past decade, a number of studies reported point mutations in the hCRT-1 protein; these have been associated with the X-linked cerebral creatine deficiency syndrome resulting from a loss of function of CRT-1: the creatine transporter deficiency syndrome affects the brain, skeletal muscle and other organs to a variable degree. Symptoms range from epilepsy, moderate to severe mental retardation, autism, development delay (in walking and speech), abnormal behaviour (attention deficit hyperactivity disorder/ADHD, shyness, aggression, self-injury) and motor dysfunction (stiff gait, coordination dysfunction and dystonia) to gastrointestinal symptoms (neonatal feeding difficulties, vomiting, constipation, ulcers) (Hahn et al., 2002; Rosenberg et al., 2004; Lion Francois et al., 2006; van der Kamp et al., 2013; Ardon et al., 2016; Uemura et al., 2017; Heussinger et al., 2017) . Based on a study of 188 consecutive mentally retarded children, the prevalence of creatine transporter deficiency was estimated to be 2.7 % (Lion- François et al., 2006) . However, this percentage rises to 4.4 %, if only boys are taken into account. The ratio of 2.7% to 4.4% shows that girls are also affected in spite of the X-linked nature of genetic transmission. In the presence of mutations, all males and about 50 % of the affected females display intellectual and cognitive dysfunction (DesRoches et al., 2015) . The nature of the mutation is an important determinant for the phenotypic consequence. In fact, only mild neuropsychological impairments were observed in several cases, where female relatives were heterozygous for mutations, e.g. for the G381R and R514X variants (Lion-François et al., 2006) . The estimated carrier prevalence of CTD in females in the general population is at least 0.024 % (DesRoches et al., 2015) . The true prevalence of creatine transporter deficiency may be underrated; the reason for this being either misdiagnosis or underdiagnosis, as most CTD patients are diagnosed with other neurological disorders such as autism, ADHD, or unexplained mental retardation.
Apart from a few mutations, which affect intracellular and extracellular loops of hCRT-1, the mutations are primarily found in the hydrophobic core of the transporter; in fact, TMDs 7 and 8 appear to be a hot spot for mutations (Freissmuth et al., 2018) . Several mutations are found at positions, which are conserved in SLC6 transporters, e.g. a single point mutation in TM3, which induces a sleepless phenotype in the Drosophila dopamine (dDAT-G108Q) (Kasture et al., 2016) , leads to severe mental retardation in children when mutated at the equivalent M A N U S C R I P T
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4 glycine residue in hCRT-1 (hCRT-1-G132V) (Lion-Francois et al., 2006) . Similarly, the P554L mutation causes Parkinsonism/dystonia in hDAT and triggers drug-resistant epilepsy in children harbouring the same mutation in CRT-1. Currently, there is no effective treatment for patients suffering from creatine transporter deficiency: the current standard therapy relies on supplementation of creatine monohydrate, L-arginine and glycine, but a long-term study of children only showed that short term benefits did not translate into a sustained improvement (van der Kamp et al., 2012) ; the symptoms substantially deteriorated in those patients who survived into adulthood. This unmet medical need justifies the search for effective therapeutic strategies in the treatment of creatine transporter deficiency. In the present study, we explored the hypothesis that many of the mutations, which trigger creatine transporter deficiency, result in misfolding of hCRT-1 and that this folding deficiency can be corrected by pharmacological means. 
Material and Methods
Chemicals
[ 3 H]Creatine (creatine [N-methyl- 3 H],
Creatine uptake assays
[ 3 H]Creatine uptake was performed as described previously (Strumann et al. 2006 ) with some modifications: 24 h after transfection, HEK293 cells were seeded onto 48-well plates (6 × 10 5 /well) pre-coated with poly-D-lysine. The following day, the medium was removed, and cells were washed twice with 1 ml Hanks` Balanced Salt Solution (Sigma 55037C) and serum-starved for 30 min at 37°C in Hank's Balanced Salt Solution. The cells were then washed twice using Krebs-HEPES buffer (10 mM HEPES.NaOH, pH= 7.4, 4.7 mM KCl, 2.2 mM CaCl 2 , 1.2 mM MgSO 4 , 10 mM glucose, 120 mM NaCl). For uptake, the cells were incubated in uptake buffer containing 10 nM [
Enzymatic deglycosylation and immunoblotting
After 24 h, transiently transfected HEK293 cells were split and incubated in the presence or absence of 4-PBA (5 mM). After another 24 h, cells were lysed in a buffer containing 50 mM Tris.HCl (pH 8.0), 150 mM NaCl, 1% dodecylmaltoside, 1 mM EDTA and protease inhibitors (Roche Complete TM ); the lysates were rotated at 4 °C for 1h. Insoluble material was removed by centrifugation (30 min at 13,000 g at 4 °C). Aliquots of the lysate (protein content 20 µg)
were incubated in the absence and presence of PNGase F, O-glycosylation and endoglycosidase H and using the NEB assay kit according to the protocol of the manufacturer.
Proteins (20 µg) were separated by denaturing polyacrylamide gel electrophoresis (resolving gel 7% monomer concentration) and transferred onto nitrocellulose membranes. These were first blocked with 3% bovine serum albumin in Tris-buffered saline containing 0.1% Tween 20 (TBST) and then a rabbit polyclonal antibody directed against GFP overnight at 4 °C.
After repeated washes, the immunoreactivity was detected by chemoluminescence (Amersham ECL Prime Western Blotting Detection Reagent) using a horseradish peroxidase-(HRP)-conjugated secondary antibody (1:5000). Immunostaining with an antiserum, which recognizes all G protein β-subunits (Hohenegger et al., 1996) , was used to verify comparable loading of individual lanes.
Laser scanning microscopy and image analysis
HEK293 cells expressing wild-type hCRT-1-YFP or mutants of interest were seeded onto 8-well ibidi® glass-bottomed µ-slides. The incubation with 4-PBA was done as described above (see 2.5.). Images were captured on a Zeiss LSM780 equipped with an argon laser (at 30 milliwatts) and a 63× oil immersion objective (Zeiss Plan-Neofluar). Trypan blue solution (0.05 % in PBS) was used to stain the plasma membranes, as described previously (Sucic et al., 2010) . The images were analyzed using Image J. ImarisColoc function of Bitplane Imaris As described in Geier et al. (2011) , hippocampi from neonatal Sprague-Dawley rats were dissected to prepare primary cultures of hippocampal neurones, which were seeded onto 3.5 cm glass bottom cell culture dishes. DMEM high glucose with l-glutamine (PAA, Pasching, Austria) supplemented with 10% heat-inactivated foetal calf serum (Invitrogen, Lofer, Austria) was used as a culture medium. Neurones were cultured at 37°C and 5% CO 2 . Oneweek-old neurons were transfected with plasmids (1 µg) encoding WT hCRT1-YFP and hCRT1-P544L-YFP using Lipofectamine 2000 (3 µl in 0.5 ml) according to the manufacturer's protocol. After 24 h, neurones were incubated in the presence of 4-PBA for transfection for an additional 24 h period. Thereafter, neurones were fixed in 3.7%
paraformaldehyde in PBS for 20 min at room temperature. Images were captured by confocal microscopy under oil immersion (63x objective, numerical aperture 1.4) with a Zeiss LSM780 confocal microscope. Images were analysed using the Image J software. The Sholl analysis plugin was used to measure the distribution of hCRT-1-YFP and -P544L mutant across the neurites, with radii increasing in 2 µm increments. The distribution of wild type and mutant CRT-1 was quantified by calculating the area under the curve (AUC) for the different conditions. The Kruskal-Wallis test followed by Dunn's multiple comparison was used to calculate statistical differences in the distribution pattern of wild type and mutant hCRT-1.
Results
Naturally occurring variants of hCRT-1 trigger disease due to protein misfolding
All constructs were tagged with yellow fluorescent protein (YFP) to examine their subcellular distribution. We verified that this C-terminal tag did not impair the kinetics of transport: substrate uptake of tagged and untagged hCRT-1 were comparable (data not shown). We selected sixteen naturally occurring variants of the hCRT-1, which had been identified in children suffering from the creatine transporter deficiency (CTD) syndrome, primarily manifested by mental retardation in the afflicted patients. The mutations are scattered throughout the hCRT-1 protein, both in the transmembrane and loop regions of the transporter (for the homology model, see Freissmuth et al., 2018) . When heterologously expressed in HEK293 cells, all hCRT-1 variants proved to be loss-of-function mutants ( Fig. 1 ): the majority of the mutants did not support any appreciable creatine uptake; however, in several of the mutants (i.e.
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8 R391W, A404P, V539I and P544L), creatine uptake reached some 10-20 % of wild type uptake levels ( Fig. 1) . Abolition of uptake can have many causes, e.g. a mutation may trap the transporter in a conformational state and thus block progression through the transport cycle and/or impair trafficking/surface expression of the transporter and/or result in the loss of affinity for the endogenous substrate creatine. For the 16 hCRT-1 mutants examined here, we found that the functional deficit was due to their absence at the plasma membrane: confocal laser scanning microscopy of C-terminally YFP-tagged hCRT-1 mutants revealed that most mutations led to the entrapment of the protein within the cell ( Fig. 2) : their distribution was superimposed with that of calnexin, an endoplasmic reticulum (ER)-resident chaperone. In contrast, the wild type hCRT-1 was targeted to the cell surface and co-localised with trypan blue (the Pearson coefficient for WT hCRT-1-YFP was 0.6, and was negative for all the mutants), which was used to delineate the plasma membranes ( Fig. 2 , left hand top row).
The response of hCRT-1 mutants to small molecules
The retention of the hCRT-1 mutants in the ER is indicative of their misfolding. Folding (Christie, 2007) . Digestion by PNGAse F removed most of the heterogeneity (second lane in Fig. 3B ). In contrast, Endo H only cleaved the lower bands, the mobility of the upper bands was not affected (last lane in Fig. 3B ). We noted that treatment with PNGase F did not eliminate all heterogeneity, i.e. the band (labelled D in Fig. 3B ) was still broad. Accordingly, we searched for possible additional modifications: three O-linked glycosylation sites were predicted by NetOglyc software (Steentoft et al. 2013) were removed (lane 4 in Fig. 3B , bands labelled by a red circle). Based on the susceptibility to enzymatic digestion, we conclude that the upper and the lower bands represent the mature glycosylated species (labelled M in Fig. 3B ) and the ER-resident core-glycosylated protein (labelled C in Fig. 3B ), respectively.
We tested the response of hCRT-1 mutants to the chemical chaperone 4-phenyl butyrate (4-PBA) and the inhibitors of heat shock proteins (HSP) pifithrin-µ and 17-DMAG. Upon incubation of cells with 4-PBA (5 mM), HSP70 blocker pifithrin-µ (5 µM) or HSP90 blocker 17-DMAG (2 µM), we observed increases in total protein expression of most variants of hCRT-1 examined. The quantification indicated that there was a robust and statistically significant increase in the mature glycosylated bands of 6 mutants -i.e., hCRT-1-R391W, -A404P, -G424D, -V539I, -P544L and -P554L (see bar graphs in Fig. 4 ) -upon treatment with 5 mM 4-PBA. The effects produced by either pifithrin-µ or 17-DMAG were not as pronounced as those achieved by 4-PBA (Fig. 4) .
Treatment with 4-PBA restores the activity of several CTD-inducing variants, R391W, A404P, G424D, V539I and P544L
Transporters can only take up the substrate, if they reach the plasma membrane. The preincubation with 5 mM 4-PBA also restored substrate transport by these six CTD-triggering variants, namely hCRT-1-R391W, -A404P, -G424D, -V539I, -P544L and -P554L (Fig. 5 ), which had been identified based on their glycosylation pattern (Fig. 4) . Several mutants were responsive to 4-PBA. For further characterization, we selected one mutation from an extracellular loop (R391W in EL4), two mutations (A404P and G424D) from TM8 (a helix, which is a hot spot for mutations and which is though to line the translocation pathway) and one (P544L) from TM11, which represents a separate domain in SLC6 transporters, i.e. it is not part of the inverted repeat. Two additional mutants, C337W and A448D, also show some degree of rescue by 4-PBA, albeit to a relatively modest extent of 5-10 % of the wild type control (Fig. 5) . Because of the micro-heterogeneity of hCRT1 (see Fig. 3 ), we verified by enzymatic digestion that the mature glycosylated was formed, for both the wild type protein and the mutants, in the presence of 4-PBA (Fig. 6 ). Only the wild type transporter and 4-PBAresponsive mutants (shown for hCRT-1-R391W, -A404P, -G424D and -P544L in Fig. 6 ) revealed mature glycosylated, endoglycosidase H-resistant species. In contrast, the Y80H variant, which was irresponsive to the action of 4-PBA (Fig. 5) , contained predominantly the core-glycosylated, i.e. ER-resident transporter. We confirmed these data for two responsive M A N U S C R I P T
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10 mutants, hCRT-1-R391W and hCRT-1-P544L, by confocal microscopy: after 4-PBA treatment, the rescued mutants were found at the cell surface; the YFP-fluorescence colocalised with trypan blue fluorescence, which was used to delineate the plasma membrane (Fig. 7) . Finally, we also examined the kinetics of creatine uptake for these two mutants prior to and after rescue with 5 mM 4-PBA (Fig. 8A-C) . The treatment of HEK293 cells expressing the hCRT-1-R391W and -P544L with 4-PBA resulted in an approximately 3-4-fold increase in the maximum transport velocity V max values (Table 1) .
4-PBA treatment promotes the distribution of hCRT-1-P544L, a CTD-inducing variant, into the neurite extensions of isolated hippocampal neurons.
CRT-1 is expressed in several brain areas including the hippocampus (Dodd et al., 2010) ; in hippocampal neurons, CRT-1 is delivered to both, dendrites and axons (Dodd et al., 2010) .
Accordingly, we compared the distribution of YFP-tagged wild type hCRT1 and hCRT1-P544L variant in hippocampal neurones: wild type hCRT1 was visualized throughout the arborisations of the neurite extensions and reached their distal tips (Fig. 9A) . In contrast, the pathological variant hCRT1-P544L was confined to the neuronal soma and only entered the proximal segments of the neurites (Fig. 9B) . However, if the neurones were incubated in the presence of 5 mM 4-PBA for 24 h, the distribution of hCRT1-P554L-YFP became similar to that of wild type hCRT1 (cf. Fig. 9C and A) . We quantified these distributions by Sholl analysis (Fig. 9D , left hand panel) and calculated the area under the curve (AUC) for each individual neuron, which had been examined by confocal microscopy (Fig. 9D , right hand panel): these AUC-values differed in a statistically significant manner for neurons expressing wild type hCRT-1 and hCRT-1-P544L. In addition, the AUC-based analysis confirmed that 4-PBA enhanced the delivery of hCRT-1-P544L to the distal segments of the neurite extensions, such that its pattern resembled distribution of wild type hCRT-1.
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Discussion
To the best of our knowledge we are the first to report that 4-PBA can effectively rescue the activity of several pathological hCRT-1 variants linked to CTD. 4-PBA is an approved drug, which is clinically used in the chronic management of urea cycle disorders in children,
i.e. diseases caused by genetic defects in several enzymes involved in the urea cycle.
Deficiency of these enzymes (i.e. carbamoyl phosphate synthetase I, ornithine transcarbamylase, argininosuccinate synthetase, argininosuccinate lyase, arginase I, citrin and ornithine translocase) leads to nitrogen waste build up in the blood plasma, forming ammonia glutamine. 4-PBA acts as a nitrogen-scavenger and assists kidneys in excreting excess ammonia from the body. Besides, 4-PBA is used for sickle cell disease due to its capacity to activate β-globin transcription (Dover et. al, 1997; Qi et al., 2004) and is also under clinical investigation for use in cancer and Huntington´s disease (Kolb et al., 2015) . Moreover, the merits of 4-PBA in the therapy of cystic fibrosis are well renowned. Treatment with 4-PBA induces CFTR channel function in ∆F508-CFTR-expressing cystic fibrosis airway epithelial cells (Rubenstein and Zeitlin, 1997) . This is achieved by 4-PBA stabilising the misfolded ∆F508-CFTR variant in the ER and allowing it to traffic to the cell membrane, though the mechanistic details underlying this effect happen to be more complex than initially assumed (Brodsky, 2001 ). We also observed that 4-PBA increased both, the ER-resident core glycosylated and the mature glycosylated species of wild type hCRT1 and of the responsive CTD mutants. This increase in total transporter levels does not per se argue against a chaperoning action of 4-PBA: the transporter must be first stabilised in the ER and subsequently exported. This is actually also seen with receptor ligands, which act as pharmacochaperone: in fact, in response to antagonists, a folding-deficient mutant of the A 1 -adenosine receptors is stabilised and first accumulates in the ER, because it escapes ERassociated degradation . Regrettably none of the misfolded DAT variants linked to infantile/juvenile parkinsonism and dystonia (Kurian et al., 2009 (Kurian et al., , 2014 Ng et al., 2014) responded to 4-PBA treatment (Asjad et al., 2017) . Surprisingly, the closely related serotonin transporter (SERT), showed marked increases in surface expression upon exposure to low mM concentrations of 4-PBA (Fujiwara et al., 2013) . We further substantiated this finding for folding-deficient versions of SERT (El-Kasaby et al., 2014; Koban et al., 2015) , which responded to 4-PBA treatment (El-Kasaby, Sucic and Freissmuth, unpublished data) . Pomozi et al., 2017) . 4-PBA has been classified as a hydrophobic chaperone, which interacts with hydrophobic segments of unfolded proteins and protects them from aggregation. In addition, 4-PBA is known to reduce ER stress through molecular mechanisms, which apparently affect many levels of regulation. Some studies allude to synergistic actions of 4-PBA, such as e.g. downregulation or modulation of HSC70 expression (Rubenstein and Zeitlin, 2000) , increase in HSP70 levels (possibly as a secondary effect of decreasing HSC70 levels), reversible histone deacetylase (HDAC) class I and IIa inhibition (Cousens et al., 1979; Konsoula and Barile, 2012) , and signaling via Elp2 and STAT-3 (Suaud et al., 2011).
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4-PBA-induced inhibition of HDACs leads to transcriptional regulation of genes in the unfolded protein response (UPR) system. This in turn induces the synthesis of molecular chaperones (HSPs) and downregulation of protein synthesis (Cortez and Sim, 2014) . In fact, the neuroprotective effects of 4-PBA may be accounted to epigenetic regulators related to HDAC inhibition related to enhanced synaptic plasticity, learning and memory (Konsoula and Barile, 2012) . Accordingly, 4-PBA showed beneficial effects in various cell culture and animal models of neurodegenerative disorders, e.g. Alzheimer´s (Ricobaraza et al., 2009 (Ricobaraza et al., , 2012 and Parkinsons´s disease (Inden et al., 2007; Ono et al., 2009) .
It is worth mention that several pathological variants found in the hCRT-1 also trigger folding diseases at equivalent positions in other SLC6 family members. For instance, the replacement of glycine 132 by valine in hCRT-1 (i.e G132V-hCRT-1 variant) causes severe mental retardation in boys (Lion-Francois et al., 2006) , and the mutation to glutamine of the equivalent glycine in Drosophila melanogaster DAT (i.e. G108Q-dDAT), leads to a sleepless phenotype reminiscent of a DAT knock-out in flies (Kasture et al., 2016 (Kasture et al., , 2017 . Similarly, the mutation of P554 to leucine (L) elicits misfolding in both transporters and consequently leads to disease: infantile/juvenile parkinsonism-dystonia in hDAT (Kurian et al., 2009 (Kurian et al., , 2011 Ng et al., 2014; Asjad et al., 2017) , and severe mental retardation in hCRT-1 (Rosenberg et al., 2004 (Rosenberg et al., , 2007 Mancini et al., 2005) . The same holds true for the mutation to leucine (L) of P390 in hCRT-1 and the equivalent residue P395 in hDAT. P544 and P554 are located within TMD11 and the extracellular loop between TMDs 11 and 12, respectively. The proline residue P390-hDAT/P395-hCRT-1 is located in TMD8. At least seven CTD-causing hCRT-1 mutations reported to date are substitutions of prolines by other residues, leucine being the most frequent substitution (i.e. P382L, P295R, P390L, P434L, P544L, P554L and P597T).
Prolines are known to induce kinks in proteins and their replacement by other residues is likely to perturb the protein structure, which in many instances accounts for folding defects.
Proline is the only natural amino acid whose side chain connects to the protein backbone M A N U S C R I P T
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13 twice, forming a five-membered nitrogen-containing ring. The main chain conformations that can be adopted by prolines are hence limited in comparison to any other amino acid.
On a clinical level, CTD encompasses a vast range of symptoms contingent on the particular variant. Some mutations elicit much graver phenotypes than others. The R391W variant is accompanied by speech delay, hyperactivity and abnormal behavior, as well as myoclonic seizures (Mencarelli et al., 2011) . Another CTD variant associated with epilepsy is hCRT1-P544L; it is manifested by moderate mental retardation, delayed language and motor development, but accompanied by multifocal epileptic waves (Mancini et al., 2005; Betsalel et al., 2012) . The P554L variant leads to hypotonia, severe intellectual disability and drugresistant epilepsy, and sudden death of one patient at the age of 17 (Rosenberg et al., 2004; Nozaki et al., 2015) . One clinical study reported significantly higher levels of guanidinoacetic acid (GAA) in the brains of CTD patients, with creatine being virtually absent (Sijens et al., 2005) . CRT-1 is known to play a role in the transport of GAA in the brain and the blood cerebrospinal fluid barrier, albeit with a K M value 10-fold greater than that of creatine (Tachikawa et al., 2008) . The lack of functional CRTs in CTD leads to cerebral accumulation of GAA. Because GAA is an endogenous convulsant, this may account for at least some of the epileptic seizures observed in many CTD patients. At this point, none of the currently available therapeutic interventions can ameliorate the clinical outcome in any of the diagnosed CTD patients. One likely rationalisation for this is that creatine is released from central neurons and exerts its action as a neuromodulator (Almeida et al. 2006) . In effect,
hCRT-1 must play a major role in taking up the previously released creatine (Peral et al. 2010 ) and/or releasing creatine from neurons (Mak et al. 2009 ). Consequently, even though supplementation with creatine itself might improve creatine levels, it cannot compensate for the neuromodulatory action accomplished by the plasmalemmal hCRT-1. We postulate that in CTD, hCRT-1 is absent from its physiological site of action in neuronal cells. The localisation of hCRT-1 in the human brain was mapped out using immunohistochemistry: the transporter is robustly expressed in the large projection neurones of the brain and spinal cord (i.e in the pyramidal neurones in the cerebral cortex, Purkinje cells in the cerebellar cortex and motor neurones of the somatic motor and visceromotor cranial nerve nuclei and the ventral horn of the spinal cord), while only negligible levels of CRT-1 were mapped to substantia nigra and locus coeruleus, i.e. regions typically implicated in neurodegenerative diseases (Lowe et al., 2015) . The absence of functional CRTs in brain cells portends that the energy normally conferred by creatine is no longer attainable, since creatine is taken up and/or released from these cells via membrane-bound CRTs. Since many CTD-triggering variants of hCRT-1 are M A N U S C R I P T
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confined to the ER due to protein folding defects, 4-PBA treatment may be the key to tackling CTD, by rectifying their folding, trafficking and transport activity. Proper trafficking, e.g.
axonal targeting of SERT in rat dorsal raphe neurons is specified by SEC24C-dependent ER export (Montgomery et al., 2014) . SERT mutants, which are either folding-deficient or harbour a disrupted SEC24C-recognition motif are also trapped in the ER (Sucic et al, 2011 (Sucic et al, , 2013 . The same holds true for misfolded variants of hDAT associated with infantile Parkinsonism/dystonia; several of which were functionally rescued by pharmacochaperoning, both in HEK293 cells and in living flies (Kasture et al., 2016; Asjad et al., 2017) .
Several groups studied CTD mouse models, which largely mimicked the symptoms (i.e.
impaired cognition and autistic-like behaviour) of the human disease (Kurosawa et al, 2012; Baroncelli et al, 2016; Stockebrand et al, 2018) . The CRT-1 knockout mice showed a drastic deterioration in the GABAergic system, reduced hippocampal neurogenesis, prominent activation of microglia and altered oxidative metabolism (Baroncelli et al, 2016) . This explains some of the epilepsy symptoms experienced by many CTD patients. To date, only
Kurosawa and co-workers explored the possible therapeutic options for managing CTD,
showing that, in contrast to creatine itself, its analogue cyclocreatine enhanced cognitive abilities in mice with a brain-specific CRT-1 knock-out (Kurosawa et al., 2012) . Our data suggest that 4-PBA may be an effective strategy for treating CTD. 4-PBA is administered in doses of up to 20 g/d and 0.5 g/kg/d for adults and children <20 kg, respectively. Therapeutic doses translate into plasma concentrations ≥1 mM. Thus, it may be justified to test 4-PBA in patients harbouring those mutations, which we found to be responsive when expressed in HEK293 cells. More importantly, our work provides a proof-of-principle that the folding deficiency of mutant hCRT-1 variants is amenable to pharmacological correction. This justifies the search for additional and possibly improved pharmacochaperones.
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